echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > New indications for BeiGene Zebutinib Capsules are about to be approved

    New indications for BeiGene Zebutinib Capsules are about to be approved

    • Last Update: 2021-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 7, the official website of the State Food and Drug Administration showed that BeiGene Zebutinib Capsule's new adaptation marketing application (acceptance number CXHS2000037) was in the "under review" stage and will be approved by the NMPA in the near future
    .


    For the treatment of adults with Waldenstrom's macroglobulinemia (WM), this will be the third indication for the product to be approved


    A single-arm, open, multi-center, pivotal Phase II clinical trial code-named BGB-3111-210 evaluated the efficacy of Zebutinib in the treatment of R/R WM Chinese patients
    .


    A total of 44 patients were enrolled in the trial


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.